Drug Profile
Amfetamine extended-release - Tris Pharma
Alternative Names: Amfetamine XR - Tris Pharma; AMPH EROS; Dyanavel XR; TRI 102Latest Information Update: 21 Dec 2022
Price :
$50
*
At a glance
- Originator Tris Pharma
- Class Amphetamines; Antipsychotics; Behavioural disorder therapies; Small molecules
- Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants; Trace amine-associated receptor 1 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Attention-deficit hyperactivity disorder
- Discontinued Diabetes mellitus
Most Recent Events
- 01 Dec 2022 Amfetamine extended-release licensed to Pediatrix Therapeutics in China
- 16 Aug 2022 Launched for Attention-deficit hyperactivity disorder (In adolescents, In children, In adults) in USA (PO)
- 22 Jul 2022 Efficacy data from a phase-III trial for Attention-deficit hyperactivity disorder (In adults, In volunteers) released by Tris Pharma (NCT03834766)